World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
127
Citations
70424
World Ranking
2801
National Ranking
1563

C. Kent Osborne publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where C. Kent Osborne sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 340 publications — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

C. Kent Osborne D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where C. Kent Osborne sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 127 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

C. Kent Osborne is affiliated with Baylor College of Medicine in the United States and specializes in research primarily within the fields of medicine and biochemistry, genetics, and molecular biology. Their work focuses notably on oncology, radiology, nuclear medicine and imaging, pulmonary and respiratory medicine, genetics, and molecular biology as subfields of study.

The scientist's research predominantly covers topics related to HER2/EGFR in cancer research, monoclonal and polyclonal antibodies research, advanced breast cancer therapies, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, chronic myeloid leukemia treatments, and chronic lymphocytic leukemia research.

Their recent publications include:

  • Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models (2020, Cancer Research)
  • Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models (2021, Cancer Research)
  • Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer (2021, Cancer Research)
  • Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models (2021, Cancer Research)
  • Abstract SP139: HER2 targeted therapy: Determinants of response and mechanisms of resistance (2021, Cancer Research)

Frequent co-authors of C. Kent Osborne include:

  • Mothaffar F. Rimawi
  • Rachel Schiff
  • Jamunarani Veeraraghavan
  • Sarmistha Nanda
  • Martin J. Shea

Key publication venues where their work appears most often are:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • ESMO Open
  • bioRxiv (Cold Spring Harbor Laboratory)

C. Kent Osborne has been recognized as a member of the Association of American Physicians. Their research contributions offer insights into molecular mechanisms of breast cancer resistance and targeted therapies, emphasizing the development of therapeutic strategies in oncology.

Best Publications

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

    Jennet M. Harvey;Gary M. Clark;C. Kent Osborne;D. Craig Allred

  • Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

    Xiaoxian Li;Michael T. Lewis;Jian Huang;Carolina Gutierrez

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

    Jiang Shou;Suleiman Massarweh;C. Kent Osborne;Alan E. Wakeling

  • Mechanisms of Endocrine Resistance in Breast Cancer

    C. Kent Osborne;Rachel Schiff

  • Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

    Matthew D. Burstein;Anna Tsimelzon;Graham M. Poage;Kyle R. Covington

  • Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

    Jenny C. Chang;Eric C. Wooten;Anna Tsimelzon;Susan G. Hilsenbeck

  • Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

    C. Kent Osborne;Valerie Bardou;Torsten A. Hopp;Gary C. Chamness

  • Treatment of HER2-positive breast cancer: current status and future perspectives

    Carlos L. Arteaga;Mark X. Sliwkowski;C. Kent Osborne;Edith A. Perez

  • Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

    Valerie Jeanne Bardou;Grazia Arpino;Richard M. Elledge;C. Kent Osborne

  • Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

    Christopher C. Benz;Gary K. Scott;Jay C. Sarup;Randolph M. Johnson

  • The value of estrogen and progesterone receptors in the treatment of breast cancer

    C. Kent Osborne;Michael G. Yochmowitz;William A. Knight;William L. McGuire

  • Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

    D. C. Allred;G. M. Clark;R. Elledge;S. A. W. Fuqua

  • Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

    Robert M. Lavinsky;Kristen Jepsen;Thorsten Heinzel;Joseph Torchia

  • Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

    Grazia Arpino;Lisa Wiechmann;C. Kent Osborne;Rachel Schiff

  • Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy

    Xiaojiang Cui;Rachel Schiff;Grazia Arpino;C. Kent Osborne

  • Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

    Richard M. Elledge;Gary M. Clark;Gary C. Chamness;C. Kent Osborne

  • Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

    M. Carolina Gutierrez;Simone Detre;Stephen Johnston;Syed K. Mohsin

Frequent Co-Authors

Rachel Schiff
Rachel Schiff Baylor College of Medicine
Susan G. Hilsenbeck
Susan G. Hilsenbeck Baylor College of Medicine
D. Craig Allred
D. Craig Allred The University of Texas Health Science Center at San Antonio
Suzanne A. W. Fuqua
Suzanne A. W. Fuqua Baylor College of Medicine
Chad J. Creighton
Chad J. Creighton Baylor College of Medicine
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
Gary M. Clark
Gary M. Clark The University of Texas Health Science Center at San Antonio
Jenny C. Chang
Jenny C. Chang Houston Methodist
Chad A. Shaw
Chad A. Shaw Baylor College of Medicine
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a future in Medicine, there are several online degree and career advancement options to explore. For those seeking a flexible and affordable education, cheap online nursing programs provide a popular route toward starting a nursing career without the high tuition costs often associated with traditional colleges.

Existing registered nurses (RNs) looking to advance their qualifications may find rn to bsn online degree options appealing. These programs are designed to fit around work schedules and enable RNs to build on their clinical skills and open up new job opportunities.

Ambitious nurses interested in the highest levels of research or academic roles can pursue online phd programs in nursing. These flexible doctorates are ideal for those who want to balance professional commitments with further education.

For individuals with a non-nursing background hoping to shift into nursing and healthcare leadership, direct entry msn programs for non-nursing majors can accelerate your transition. These online options help you gain essential medical knowledge and credentials, even if you did not major in nursing.

Best Scientists Citing C. Kent Osborne

Trending Scientists

Recently Published Articles